Pfizer (NYSE:PFE) Price Target Raised to $27.00 at UBS Group

Pfizer (NYSE:PFE) had its price objective increased by UBS Group from $25.00 to $27.00 in a research note published on Monday morning,Benzinga reports. UBS Group currently has a neutral rating on the biopharmaceutical company’s stock.

Other equities analysts have also recently issued research reports about the company. Morgan Stanley lifted their price objective on Pfizer from $27.00 to $28.00 and gave the company an “equal weight” rating in a research note on Friday. HSBC lifted their price objective on Pfizer from $29.00 to $32.00 and gave the company a “buy” rating in a research note on Tuesday, March 17th. Bank of America decreased their price objective on Pfizer from $27.00 to $26.00 and set a “neutral” rating for the company in a research note on Thursday, April 9th. Cantor Fitzgerald reiterated a “neutral” rating and issued a $27.00 price objective on shares of Pfizer in a research note on Wednesday, February 4th. Finally, Guggenheim boosted their target price on Pfizer from $35.00 to $36.00 and gave the stock a “buy” rating in a research note on Tuesday, March 24th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, fourteen have given a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and an average price target of $28.24.

Pfizer Stock Performance

Shares of PFE opened at $27.32 on Monday. The stock has a 50-day simple moving average of $27.22 and a 200-day simple moving average of $25.98. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.87 and a current ratio of 1.16. The stock has a market capitalization of $155.37 billion, a PE ratio of 20.09 and a beta of 0.43. Pfizer has a 1 year low of $21.87 and a 1 year high of $28.75.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.57 by $0.09. The business had revenue of $17.56 billion during the quarter, compared to analysts’ expectations of $16.93 billion. Pfizer had a return on equity of 20.48% and a net margin of 12.42%.The business’s quarterly revenue was down 1.2% compared to the same quarter last year. During the same quarter last year, the business posted $0.63 EPS. On average, analysts predict that Pfizer will post 2.95 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Pfizer

Several institutional investors have recently added to or reduced their stakes in PFE. Norges Bank purchased a new stake in Pfizer during the fourth quarter worth approximately $1,830,986,000. Morgan Stanley lifted its stake in Pfizer by 19.2% in the fourth quarter. Morgan Stanley now owns 89,113,604 shares of the biopharmaceutical company’s stock valued at $2,218,929,000 after buying an additional 14,342,946 shares during the last quarter. Bank of New York Mellon Corp lifted its stake in Pfizer by 38.9% in the fourth quarter. Bank of New York Mellon Corp now owns 48,514,971 shares of the biopharmaceutical company’s stock valued at $1,208,023,000 after buying an additional 13,581,757 shares during the last quarter. Franklin Resources Inc. lifted its stake in Pfizer by 47.8% in the third quarter. Franklin Resources Inc. now owns 25,070,148 shares of the biopharmaceutical company’s stock valued at $638,787,000 after buying an additional 8,108,887 shares during the last quarter. Finally, Janus Henderson Group PLC lifted its stake in Pfizer by 577.5% in the fourth quarter. Janus Henderson Group PLC now owns 8,786,084 shares of the biopharmaceutical company’s stock valued at $218,817,000 after buying an additional 7,489,189 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Key Headlines Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer renewed a licensing agreement with Trellus Health to continue using patient‑support educational content for its IBD digital app — supports recurring non‑drug revenue and digital patient engagement efforts. Trellus Health shares jump 39% on Pfizer deal renewal
• Positive Sentiment: Two outlets reported analyst price target uplifts: AmericanBankingNews noted a raise to $28.00 (positive for sentiment), and UBS raised its target to $27 (while keeping a Neutral rating) — these lifts can support the stock despite mixed conviction. Pfizer (PFE) Price Target Raised to $28.00
• Positive Sentiment: Coverage note: Zacks highlighted Pfizer’s outperformance vs. the broader market, reflecting short‑term bullish momentum among investors. Pfizer (PFE) Outperforms Broader Market: What You Need to Know
• Neutral Sentiment: Pfizer Limited corrected a technical XBRL filing error — a procedural fix that removes a potential reporting concern but is unlikely to affect fundamentals. Pfizer Limited Rectifies Technical Error in XBRL Financial Filing
• Neutral Sentiment: Broader sector news (Frontier Medicines appointing an industry veteran) is unlikely to directly affect Pfizer’s stock but can influence sentiment in biotech/pharma names. Frontier Medicines Appoints Veteran Drug Development Leader David R. Epstein to Board of Directors
• Neutral Sentiment: Comparative coverage (Johnson & Johnson vs. Pfizer) highlights Pfizer’s dividend yield and valuation but offers no new company‑specific catalyst. Better Buy Right Now: Johnson & Johnson Vs. Pfizer
• Negative Sentiment: BofA trimmed its price target to $26 (from $27) and kept a Neutral rating — a downward revision that signals caution on near‑term growth and may cap upside. BofA Lowers its Price Target on Pfizer (PFE) to $26 from $27
• Negative Sentiment: Earlier analyst downgrades drove intraday weakness (reported trading down ~1.2%), reflecting continuing analyst scrutiny and potential short‑term selling pressure. Pfizer (NYSE:PFE) Trading Down 1.2% on Analyst Downgrade

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.